USP18 and neoplasm: PD-L1 protein expression in tumours has been described as a potential predictive biomarker for sensitivity to immune checkpoint blockade (ICB) with PD1/PD-L1 inhibitors.49 Also, we observed an upregulation of PD-L1 levels on the T cells when co-cultured with USP18 KO cancer cells, regardless of treatment.